ViroGates A/S

CPSE:VIRO Stock Report

Market Cap: DKK 52.4m

ViroGates Management

Management criteria checks 3/4

ViroGates' CEO is Jakob Knudsen, appointed in Apr 2011, has a tenure of 14.08 years. total yearly compensation is DKK1.61M, comprised of 90.9% salary and 9.1% bonuses, including company stock and options. directly owns 1.54% of the company’s shares, worth DKK806.24K. The average tenure of the management team and the board of directors is 7.2 years and 3.1 years respectively.

Key information

Jakob Knudsen

Chief executive officer

DKK 1.6m

Total compensation

CEO salary percentage90.91%
CEO tenure14.1yrs
CEO ownership1.5%
Management average tenure7.2yrs
Board average tenure3.1yrs

Recent management updates

Recent updates

ViroGates (CPH:VIRO) Is In A Good Position To Deliver On Growth Plans

Mar 06
ViroGates (CPH:VIRO) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That ViroGates (CPH:VIRO) Will Use Its Cash Wisely

Nov 21
We're Hopeful That ViroGates (CPH:VIRO) Will Use Its Cash Wisely

Will ViroGates (CPH:VIRO) Spend Its Cash Wisely?

Jun 14
Will ViroGates (CPH:VIRO) Spend Its Cash Wisely?

We're Not Very Worried About ViroGates' (CPH:VIRO) Cash Burn Rate

Sep 19
We're Not Very Worried About ViroGates' (CPH:VIRO) Cash Burn Rate

We Think ViroGates (CPH:VIRO) Can Afford To Drive Business Growth

Apr 14
We Think ViroGates (CPH:VIRO) Can Afford To Drive Business Growth

We Think ViroGates (CPH:VIRO) Can Afford To Drive Business Growth

Dec 30
We Think ViroGates (CPH:VIRO) Can Afford To Drive Business Growth

CEO Compensation Analysis

How has Jakob Knudsen's remuneration changed compared to ViroGates's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-DKK 14m

Dec 31 2024n/an/a

-DKK 14m

Sep 30 2024n/an/a

-DKK 13m

Jun 30 2024n/an/a

-DKK 13m

Mar 31 2024n/an/a

-DKK 13m

Dec 31 2023DKK 2mDKK 1m

-DKK 12m

Sep 30 2023n/an/a

-DKK 11m

Jun 30 2023n/an/a

-DKK 11m

Mar 31 2023n/an/a

-DKK 10m

Dec 31 2022DKK 2mDKK 1m

-DKK 10m

Sep 30 2022n/an/a

-DKK 12m

Jun 30 2022n/an/a

-DKK 13m

Mar 31 2022n/an/a

-DKK 16m

Dec 31 2021DKK 2mDKK 1m

-DKK 18m

Sep 30 2021n/an/a

-DKK 18m

Jun 30 2021n/an/a

-DKK 18m

Mar 31 2021n/an/a

-DKK 17m

Dec 31 2020DKK 2mDKK 1m

-DKK 19m

Compensation vs Market: Jakob's total compensation ($USD239.87K) is below average for companies of similar size in the Danish market ($USD375.05K).

Compensation vs Earnings: Jakob's compensation has increased whilst the company is unprofitable.

CEO

Jakob Knudsen (56 yo)

14.1yrs

Tenure

DKK 1,611,416

Compensation

Mr. Jakob Knudsen serves as Independent Director at ExpreS2ion Biotech Holding AB (publ) since 2021. He had been Director at ExpreS2ion Biotech Holding AB (publ) since April 19, 2017 until 2021. Mr. Knudse...

Leadership Team

NamePositionTenureCompensationOwnership
Jakob Knudsen
Chief Executive Officer14.1yrsDKK 1.61m1.54%
DKK 806.2k
Jesper Eugen-Olsen
Co-Founder & Chief Scientific Officer25.3yrsno data3.81%
DKK 2.0m
Josephine Jorgensen
Chief Financial Officer2.2yrsno data0.016%
DKK 8.1k
May Dyvelkov
Vice President of Accounting5.6yrsno datano data
Thomas Krarup
Vice President of Global Sales & Marketing7.2yrsno data0.21%
DKK 109.3k

7.2yrs

Average Tenure

61yo

Average Age

Experienced Management: VIRO's management team is seasoned and experienced (7.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Peter Aaby
Scientific Advisorno datano datano data
Lars Kongsbak
Non-Executive Directorno dataDKK 75.00k0.090%
DKK 47.2k
Knut Borch-Johnsen
Scientific Advisor18.3yrsno datano data
Patrik Dahlen
Independent Chairman3.1yrsDKK 150.00k0.14%
DKK 71.7k
Valerie Soulier
Independent Director3.1yrsDKK 87.85kno data

3.1yrs

Average Tenure

62.5yo

Average Age

Experienced Board: VIRO's board of directors are considered experienced (3.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/13 18:07
End of Day Share Price 2025/05/13 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ViroGates A/S is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.